OverviewSuggest Edit

Intersect ENT is dedicated to improving the quality of life for patients with ear, nose and throat conditions. The Company markets the first and only drug-releasing sinus implants, PROPEL and PROPEL mini, which are clinically proven to improve surgical outcomes for patients with chronic sinusitis. The products release an advanced steroid with anti-inflammatory properties directly into the sinus lining, then dissolve, maintaining the open passages created in ethmoid sinus surgery. In addition, Intersect ENT is pursuing clinical trials designed to support expanded indications and to assess two new investigational drug-eluting implants to provide ENT physicians with additional options to treat patients with chronic sinusitis less invasively and more cost effectively. Chronic sinusitis is an inflammatory condition leading to debilitating symptoms and chronic infections, and is one of the most costly conditions to U.S. employers.
TypePublic
Founded2003
HQMenlo Park, CA, US
Websiteintersectent.com
Employee Ratings2.5
Overall CultureC-

Latest Updates

Employees (est.) (Dec 2019)402(+3%)
Job Openings20
Revenue (FY, 2020)$80.6 M(-26%)
Share Price (Jul 2021)$19.6(-1%)
Cybersecurity ratingBMore

Key People/Management at Intersect ENT

Thomas A. West

Thomas A. West

President and Chief Executive Officer
Patrick Broderick

Patrick Broderick

Executive Vice President, General Counsel and Corporate Secretary
Reyna Fernandez

Reyna Fernandez

Chief Human Resources Officer
Rich Kaufman

Rich Kaufman

Chief Operating Officer & Senior Vice President R&D
Christine Kowalski

Christine Kowalski

Executive Vice President & Chief Operating Officer
Randy Meier

Randy Meier

Executive Vice President & Chief Financial Officer
Show more

Intersect ENT Office Locations

Intersect ENT has an office in Menlo Park
Menlo Park, CA, US (HQ)
1555 Adams Dr
Show all (1)

Intersect ENT Financials and Metrics

Intersect ENT Revenue

Embed Graph
View revenue for all periods
Intersect ENT's revenue was reported to be $80.55 m in FY, 2020
USD

Revenue (Q1, 2021)

24.3m

Gross profit (Q1, 2021)

15.9m

Gross profit margin (Q1, 2021), %

65.2%

Net income (Q1, 2021)

(20.0m)

EBIT (Q1, 2021)

(18.6m)

Market capitalization (22-Jul-2021)

659.5m

Closing stock price (22-Jul-2021)

19.6

Cash (31-Mar-2021)

14.4m

EV

663.3m
Intersect ENT's current market capitalization is $659.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

38.6m61.6m78.7m96.3m108.5m109.1m80.6m

Revenue growth, %

60%28%

Cost of goods sold

10.2m12.3m13.0m15.5m22.6m21.8m30.3m

Gross profit

28.4m49.3m65.7m80.8m85.9m87.4m50.2m
Quarterly
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

13.4m34.8m9.9m19.8m9.5m20.7m13.5m

Accounts Receivable

8.3m11.5m14.4m16.6m19.6m19.1m14.6m

Prepaid Expenses

2.9m2.7m2.3m3.5m

Inventories

951.0k1.5m1.3m8.5m11.6m17.0m12.1m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(18.4m)(26.6m)(25.2m)(16.4m)(22.9m)(43.0m)(72.3m)

Depreciation and Amortization

1.2m1.5m1.9m2.7m2.8m

Inventories

(541.0k)(544.0k)(1.7m)(2.9m)(2.5m)(5.1m)6.6m

Accounts Payable

645.0k(230.0k)1.2m203.0k2.1m(1.2m)1.5m
USDQ2, 2014

Financial Leverage

-0.2 x
Show all financial metrics

Intersect ENT Operating Metrics

Intersect ENT's Patients was reported to be 150 k in FY, 2016.
FY, 2016

Accounts

2.4 k

Patents (US)

30

Patents Pending

37

Patients

150 k
Show all operating metrics

Intersect ENT Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Intersect ENT Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Intersect ENT Online and Social Media Presence

Embed Graph

Intersect ENT Company Culture

  • Overall Culture

    C-

    65/100

  • CEO Rating

    B

    70/100

  • Compensation

    B-

    72/100

Learn more on Comparably

Intersect ENT Blogs

Intersect ENT to Report Second Quarter 2021 Financial Results on August 6

MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 23, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it will release second quarter 2021 financial results on Friday, August 6, 2021 .

Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan

Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan Content Import Thu, 07/22/2021 - 16:07 Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan Jul 22, 2021 …

Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery

Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries MENLO PARK, Calif. --(BUSINESS WIRE)--May 20, 2021-- Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming

Intersect ENT Reports First Quarter 2021 Financial Results

— Increases 2021 Revenue Guidance to $117 Million to $121 Million — MENLO PARK, Calif. --(BUSINESS WIRE)--May 10, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for

Intersect ENT Announces Appointment of New Vice President of Sales

Mark L. Alley to serve as Vice President of Sales MENLO PARK, Calif. --(BUSINESS WIRE)--May 4, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the appointment of Mark L.

Intersect ENT Announces Date Change for First Quarter 2021 Financial Results Announcement

Intersect ENT Announces Date Change for First Quarter 2021 Financial Results Announcement Content Import Thu, 04/29/2021 - 16:06 Intersect ENT Announces Date Change for First Quarter 2021 Financial Results Announcement Apr 29, 2021 This release is a backfill f…
Show more

Intersect ENT Frequently Asked Questions

  • When was Intersect ENT founded?

    Intersect ENT was founded in 2003.

  • Who are Intersect ENT key executives?

    Intersect ENT's key executives are Thomas A. West, Patrick Broderick and Reyna Fernandez.

  • How many employees does Intersect ENT have?

    Intersect ENT has 402 employees.

  • What is Intersect ENT revenue?

    Latest Intersect ENT annual revenue is $80.6 m.

  • What is Intersect ENT revenue per employee?

    Latest Intersect ENT revenue per employee is $200.4 k.

  • Who are Intersect ENT competitors?

    Competitors of Intersect ENT include Leica Microsystems, Otto Bock HealthCare and Permobil.

  • Where is Intersect ENT headquarters?

    Intersect ENT headquarters is located at 1555 Adams Dr, Menlo Park.

  • Where are Intersect ENT offices?

    Intersect ENT has an office in Menlo Park.

  • How many offices does Intersect ENT have?

    Intersect ENT has 1 office.